Approval for Nearly 1,000,000 Square Feet of Medical Cannabis Cultivation Facilities Located 47 Miles from Bostonproval for Nearly 1,000,000 Square Feet of Medical Cannabis Cultivation Facilities Located 47 Miles from Boston
DENVER, April 8, 2016 /Weed Wire/ — AmeriCann, Inc. (OTCQX: ACAN), a company that designs and develops advanced medical cannabis facilities, has released final plans for its Massachusetts Medical Cannabis Center (MMCC) development in Freetown, Massachusetts.
Please click this link to view the MMCC rendering:
The MMCC design is one of the largest and most technologically advanced cannabis cultivation facilities in the nation.
The nearly 1,000,000 square foot project will consist of multiple planned phases for tenants in the Massachusetts medical marijuana market. The first phase of the project, in Building A, consists of 130,000 sq. ft. of cultivation and processing infrastructure, which can be expanded to approximately 600,000 sq. ft, based on patient demand.
Through AmeriCann’s Preferred Partner Program, the MMCC facility will be leased exclusively to companies that have received a provisional or final registration to cultivate, process, and sell medical cannabis by the Department of Public Health.
“We believe the MMCC project will create a center of excellence and set a new standard for the entire cannabis industry for quality control, efficiency, and sustainability,” stated Ben Barton, CFO and Founder of AmeriCann. “Utilizing advanced greenhouse technology for cultivation provides our partners with the ability to produce superior sun grown medicine with far less energy and a reduced environmental impact.” MMCC is the first planned and approved greenhouse project in the Massachusetts medical marijuana market.
The facility has been designed utilizing AmeriCann’s proprietary system known as “Cannopy.” AmeriCann has drawn on its team’s extensive experience in traditional horticulture, lean manufacturing, medical research, facility construction, regulatory compliance, security, cannabis cultivation and genetics, extraction techniques, and infused product development.
The company plans to utilize the Cannopy system in the building of similar facilities in additional states and is actively seeking suitable locations for expansion.
When fully developed, MMCC is projected to create over 300 jobs with an annual projected payroll of over $14 million to the local community.
AmeriCann has been in discussions with Freetown officials for over a year and the town has provided strong support for MMCC. The Freetown planning board gave unanimous approval to the development plans in a public forum on December 8, 2015. Planning Board Chairman, Kevin Desmarais, closed the meeting by saying, “This has been one of the better public processes with which I’ve been involved. I’d like to thank the applicant [AmeriCann] for being such a professional outfit.”
The legal cannabis industry has experienced dramatic growth throughout the nation in recent years. Twenty-four states and the District of Columbia have legalized the use of medical cannabis and as many as ten additional states are expected to regulate cannabis by ballot initiative or legislatively during 2016.
The Massachusetts Medical Use of Marijuana Program, which was approved by voters in 2012 by a wide margin, continues to be one of the highest regarded markets by industry experts even with the first dispensaries having only recently opened.
A ballot initiative to allow for full marijuana legalization has received the necessary signatures and is expected to be on the November 2016 ballot for Massachusetts voters. “The state [Massachusetts] could become one of the biggest regulated cannabis markets in the country; bigger than Colorado and Washington State,” according to Marijuana Business Daily. The Boston Globe recently reported the regulated cannabis market in Massachusetts may exceed $1,000,000,000 by 2020.
AmeriCann’s Massachusetts Medical Cannabis Center Rendering:
AmeriCann, Inc., with offices in Denver, CO and Boston, MA, designs, develops, and owns advanced medical cannabis facilities to produce the best possible medical cannabis in the most efficient manner utilizing advanced, sustainable practices. The Company has over 1,000,000 square feet of facilities in development. AmeriCann does not cultivate, process, or distribute cannabis, but partners with local businesses to serve patients in their communities. More information about the Company is available at: http://americann.co
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K for the year ended September 30, 2015, including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at: http://www.sec.gov